After decades of delays, biotechs hope that bacteria-attacking viruses could provide an alternative to traditional antibiotics.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Dual functionality nanobioconjugates targeting intracellular bacteria in cancer cells with enhanced antimicrobial activity
Scientific Reports Open Access 19 July 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnrd4695/MediaObjects/41573_2015_Article_BFnrd4695_Fig1_HTML.jpg)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Kingwell, K. Bacteriophage therapies re-enter clinical trials. Nat Rev Drug Discov 14, 515–516 (2015). https://doi.org/10.1038/nrd4695
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4695
This article is cited by
-
Gut Microbiome over a Lifetime and the Association with Hypertension
Current Hypertension Reports (2021)
-
Manufacturing Stable Bacteriophage Powders by Including Buffer System in Formulations and Using Thin Film Freeze-drying Technology
Pharmaceutical Research (2021)
-
Blood pressure management in an ecosystem context
Hypertension Research (2020)
-
Gut microbiota in colorectal cancer: mechanisms of action and clinical applications
Nature Reviews Gastroenterology & Hepatology (2019)
-
Bacteriophage production processes
Applied Microbiology and Biotechnology (2019)